| 生物活性 | |||
|---|---|---|---|
| 靶点 | 
 | ||
| 描述 | Astragaloside IV(AS-IV) is a saponin from Astragalus membranaceus. Oral administration of AS-IV (10 and 20 mg/kg) significantly attenuated memory impairment and neuroinflammation[3]. High-dose astragaloside IV has a significant protective effect against D-GalN/LPS-induced (D-galactosamine/lipopolysaccharide-induced ) acute liver injury in mice [4]. High doses of astragaloside IV (10, 20, 40 ng/ml) inhibited NSCLC (non-small cell lung cancer ) cell growth[5]. Astragaloside IV inhibited the viability and invasive potential of MDA-MB-231 breast cancer cells, suppressed the activation of the mitogen activated protein kinase (MAPK) family members ERK1/2 and JNK, and downregulated matrix metalloproteases (MMP)-2 and -9[6]. | ||
| 临床研究 | |||||
|---|---|---|---|---|---|
| NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 | 
| NCT01553643 | Intracranial Arterial Stenosis | Phase 4 | Unknown | - | Taiwan ... 展开 >> China Medical University Hospital Recruiting Taiching, Taiwan Contact: Chung Hsiang Liu, MD. 收起 << | 
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
| 1 mM 5 mM 10 mM | 1.27mL 0.25mL 0.13mL | 6.37mL 1.27mL 0.64mL | 12.74mL 2.55mL 1.27mL | 
| 参考文献 | 
|---|